Atypical hemolytic uremic syndrome (aHUS) is a chronic life threatening condition that arises
from genetic abnormalities resulting in uncontrolled complement amplifying activity. The …

HUS is due to a thrombotic microangiopathy affecting mainly the kidney. In children, HUS is
most often secondary to an infection from STEC. Risk factors for poor outcomes include …

Background Infection-associated hemolytic uremic syndrome (IA-HUS), most often due to
infection with Shiga toxin-producing bacteria, mainly affects young children. It can be acutely …

Esta guía de recomendaciones para el TR de donante vivo (TRDV) es un documento
elaborado con el patrocinio de la Sociedad Española de Nefrología, la Sociedad Española …

Aims This study compared the aggregate duration of treatment administration of approved
eculizumab and ravulizumab treatment regimens and resultant productivity implications for …

Background Eculizumab modifies the course of disease in patients with atypical haemolytic
uraemic syndrome (aHUS), but data evaluating whether eculizumab discontinuation is safe …

Background Eculizumab was approved for atypical haemolytic uraemic syndrome (aHUS) in
Japan in 2013. Post-marketing surveillance (PMS) was mandated by regulatory authorities …

Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) that is
driven by uncontrolled activation of the alternative complement pathway, classically in the …

Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment
of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent …

Introduction Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic
syndrome (aHUS) are two rare and severe conditions caused by chronic complement (C') …